Over the past several years, the rise of GLP-1 drugs such as OZempec and Wagovi

has changed the conversation around weight and obesity in the U.S.

Once reserved for treating diabetes, GLP-1s are now widely available.

One recent survey found that 12% of American adults have taken a GLP1 medication and another 14% are interested in doing

so. For many people, the drugs have been life-changing, but along with physical changes,

people taking GLP-1s often need to navigate new mental health, emotional, and relationship

concerns. Now mental health professionals

are thinking about how best to support people through these challenges. So how do GLP1 drugs work?

What should people consider when they're deciding whether or not to take them? What affects

both positive and negative might these medications have on mental health?

How does weight loss affect people's relationships with their family, friends, and partners?

Why is there still stigma around the use of GLP ones?

And how can patients navigate and protect themselves from that stigma?

Welcome to Speaking of Psychology, the flagship podcast of the American Psychological Association

that examines the links between psychological science and everyday life.

I'm Kim Mills.

My guest today is Dr. Rachel Goldman, a licensed psychologist in private practice in New York

City, and a clinical assistant professor in the Department of Psychiatry at NYU.

Her practice focuses on stress management, eating behaviors, obesity treatment, and health behavior

change. From 2011 to 2016, she served as

senior psychologist at the Center for Obesity and Weight Management at Bellevue Hospital.

In addition to her clinical work, Dr. Goldman is frequently featured as a health expert in the media,

...